News
| 2 min read
AMG 634, an investigational treatment for tuberculosis and leprosy, has been licensed to Medicines Development for Global Health
| 3 min read
NBE-Therapeutics will remain at its Basel, Switzerland, campus and operate within Boehringer Ingelheim’s R&D network
| 2 min read
Positive initial casirivimab and imdevimab results in non-hospitalized COVID-19 patients were published in NEJM
| 3 min read
The five year collaboration aims to improve treatment outcomes in cardiovascular disease management in Asian patients
| 2 min read
Kineta doses first patient in Phase 1 trial of KCP506, a non-opioid treatment for chronic pain
| 2 min read
COVI-VAC is a single dose, intranasal live attenuated vaccine for COVID-19
| 3 min read
New insights into age-related macular degeneration could lead to better treatments
| 2 min read
Innovent doses first patient in Phase 2 trial of IBI310 combined with sintilimab injection for treatment of cervical cancer
| 2 min read
UK Biobank announces that 10 biopharmaceutical companies will take part in a consortium to measure circulating plasma proteins
| 2 min read
The companies' TRAMmoniTRR Study will screen TTR-positive participants to determine if they have hereditary transthyretin-related amyloidosis
| 2 min read
Friends of Cancer Research unites industry, academia and regulatory partners in an effort to realize the potential of homologous recombination deficiency in cancer prognosis
| 2 min read
Researchers have discovered that SIGLEC12 contains several features unique to humans
